News
-
23.06.2009
Salvacyl®, developed by Debiopharm, is launched in two European countries - a new therapeutic avenue for the treatment of sexual deviations - -
18.06.2009
Debiopharm Group and Moffitt Cancer Center sign development and commercialisation agreement for small molecule Debio 0928 in early preclinical development for treatment of solid tumours - A novel drug with potential to block cancer cell proliferation
Home
| Development capabilites |
|
We manage the development of our projects according to a matrix system which enables us an optimal allocation of our resources so each project can be handled in the best possible way. We have the expertise in preclinical and clinical trials, manufacturing, regulatory affairs, and innovative drug delivery and formulation.
|
|||||





